A Therapeutic Aptamer Inhibits Angiogenesis by Specifically Targeting the Heparin Binding Domain of...
A Therapeutic Aptamer Inhibits Angiogenesis by Specifically Targeting the Heparin Binding Domain of VEGF165
About this item
Full title
Author / Creator
Publisher
United States: National Academy of Sciences
Journal title
Language
English
Formats
Publication information
Publisher
United States: National Academy of Sciences
Subjects
More information
Scope and Contents
Contents
Aptamers recognize their targets with extraordinary affinity and specificity. The aptamer-based therapeutic, Macugen, is derived from a modified 2'fluoro pyrimidine RNA inhibitor to vascular endothelial growth factor (VEGF) and is now being used to treat the wet form of age-related macular degeneration. This VEGF165aptamer binds specifically to the...
Alternative Titles
Full title
A Therapeutic Aptamer Inhibits Angiogenesis by Specifically Targeting the Heparin Binding Domain of VEGF165
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pnas_primary_102_52_18902_fulltext
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pnas_primary_102_52_18902_fulltext
Other Identifiers
ISSN
0027-8424
E-ISSN
1091-6490
DOI
10.1073/pnas.0509069102
